Method for synthesizing aztreonam compound

Abstract

The invention relates to a method for synthesizing an aztreonam compound. The method comprises the following steps of: (1) adding water and a water-soluble non-aqueous solvent into a reaction container, adding trans-3(S)-amino-4-methyl-2-keto-1-azetidine sulfonic acid, triethylamine and (Z)-2-[(2-aminothiazole-4-radical)-(benzothiazole-2-sulfenyl carbonyl) methylamine oxygroup]-2-methylpropanoic acid tert-butyl ester for reacting, and adjusting the pH with acid and separating crystals out to obtain tertiary butyl aztreonam; and (2) subjecting the tertiary butyl aztreonam and acid-water mixed liquor to reaction and performing post-treatment to obtain aztreonam. By adopting the method, the reaction time can be shortened, the reaction speed can be increased, the production cost can be lowered, and environmental pollution can be reduced.

Description

technical field

[0001] The invention belongs to the technical field of medicine, and in particular relates to a method for synthesizing aztreonam compound. Background technique

[0002] Aztreonam was the first monobactam antibiotic for clinical use. Developed by Bristol-Myers Squibb, it was first launched in Italy in 1984. The chemical name is: [2S-[2α, 3β(Z)]]-2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1 -sulfo-3-azetidinyl)amino]-2-oxyethylene]amino]oxo]-2-methylpropanoic acid. Molecular formula: C 13 h 17 N 5 o 8 S. Molecular weight: 435.44. Structural formula:

[0003]

[0004] Aztreonam has a strong effect on Gram-negative bacteria and is stable to a variety of plasmid-mediated and chromosome-mediated β-lactamases. Some strains resistant to cephalosporin or penicillin antibiotics are still susceptible to aztreonam. Moreover, this product is safe and effective in clinical use, widely used in various infections, and the clinical effective rate is above ...

Images